Targeting sterol-O-acyltransferase 1 to disrupt cholesterol metabolism for cancer therapy

Teng Tu; Hongying Zhang; Huanji Xu

doi:10.3389/fonc.2023.1197502

Frontiers in Oncology (Jun 2023)

Targeting sterol-O-acyltransferase 1 to disrupt cholesterol metabolism for cancer therapy

Teng Tu,
Hongying Zhang,
Huanji Xu

Affiliations

Teng Tu: Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, China
Hongying Zhang: Laboratory of Oncogene, West China Hospital, Sichuan University, Chengdu, China
Huanji Xu: Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, China

DOI: https://doi.org/10.3389/fonc.2023.1197502
Journal volume & issue: Vol. 13

Abstract

Read online

Cholesterol esterification is often dysregulated in cancer. Sterol O-acyl-transferase 1 (SOAT1) plays an important role in maintaining cellular cholesterol homeostasis by catalyzing the formation of cholesterol esters from cholesterol and long-chain fatty acids in cells. Many studies have implicated that SOAT1 plays a vital role in cancer initiation and progression and is an attractive target for novel anticancer therapy. In this review, we provide an overview of the mechanism and regulation of SOAT1 in cancer and summarize the updates of anticancer therapy targeting SOAT1.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords